- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Irohin
-
Irohin
Ipele 2A Itoju Akàn Ẹdọfóró 2026: Data ELCC Tuntun lori Itọju ailera Neo-Adjuvant
Oye Akoonu Ipele 2A Akàn Ẹdọfóró Ẹdọfóró Ẹdọgbọn Kekere 2026 ELCC Breakthroughs ni Neo-Adjuvant Strategies Itọju Awọn Itọju Iwakọ fun Ipele Iyipada Iwakọ 2A Iṣayẹwo Iṣalaye Akàn Ẹdọfóró ti Trea...
Itoju Akàn Ẹdọfóró Indolent 2026: Awọn Ilana Tuntun fun Iwalaaye Igba pipẹ
Oye Akoonu Indolent Akàn Ẹdọfóró ni 2026 Yipada Paradigm: Lati Iṣẹ abẹ Lẹsẹkẹsẹ si Iwoye Iṣiṣẹ Iṣeduro Awọn aṣayan Iṣẹ-abẹ Invasive Kere fun Awọn Egbo Ilọsiwaju ti o farahan T…
Itọju Ẹdọfóró Akàn Aláìṣiṣẹ́ 2026: TIL Tuntun & Awọn Ipinnu Ni pato
Akoonu Awọn Iyipada Paradigm ni Itọju Ẹdọfóró Akàn Aiṣiṣẹ Ailoye Tumor-Infiltrating Lymphocyte (TIL) Therapy Bispecific Antibodies: The Dual-Target Approach Comparative Analysis of Eme...
Itọju Ẹdọfóró akàn akọkọ 2026: Awọn Itọsọna Tuntun & Awọn Iwosan Titun
Imọye Akoonu Akàn Ẹdọfóró Alakọbẹrẹ ati Awọn Ilana Imudaniloju Imudojuiwọn Awọn Itọsọna Itọju Ẹdọfóró Ẹdọfóró 2026 fun Awọn Ilọsiwaju Akàn Ẹdọfóró Ẹdọfóró Kekere ni Awọn Itọju Ẹdọfóró Ẹdọfóró Kekere…
Iṣẹ abẹ Itọju Ẹdọfóró Akàn 2026: Titun Neo-Adjuvant Breakthroughs
Akoonu Itankalẹ ti Iṣẹ abẹ Itọju Ẹdọfóró ni ọdun 2026 Awọn aṣeyọri ninu Imunotherapy-orisun Neo-Adjuvant Regimens Itọju Itọju fun Awakọ-iyipada Iyipada Awọn Alaisan rere Awọn ilana Iṣẹ abẹ…
Awọn aṣayan Itọju Ẹdọfóró Ẹdọfóró Kekere 2026: ADC Tuntun & Awọn Ipinnu Immunotherapy
Akoonu Akoonu Loye Ilẹ-ilẹ lọwọlọwọ ti Awọn aṣayan Itọju Ẹdọfóró Ẹdọfóró Ẹdọgbọn Kekere Awọn Iṣeduro Laini akọkọ: Awọn akojọpọ Ajẹsara Ajẹsara Dide ti Awọn Asopọmọra Atako-Oògùn (ADCs) Ifojusi DLL3:...
